natgillin/translations-raw huggingface dataset:
Tablet container: 30 and 250 tablets. 
Spremnik s tabletama: 30 i 250 tableta.
The mean absolute bioavailability for telmisartan is about 50%. 
Srednja vrijednost apsolutne bioraspoloživosti telmisartana je oko 50%.
Pharmacokinetic studies in patients with hepatic impairment showed an increase in absolute bioavailability up to nearly 100 %. 
Oštećenje jetre Farmakokinetička ispitivanja u bolesnika s oštećenjem jetre pokazala su porast apsolutne bioraspoloživosti do gotovo 100%.
Total plasma clearance (Cltot) is high (approximately 1,000 ml/min) compared with hepatic blood flow (about 1,500 ml/min). 
Ukupni klirens plazme (Cltot) je velik (oko 1000 ml/min) u usporedbi s protokom krvi u jetri (oko 1500 ml/min).
- Heart trouble. 
- Problemi sa srcem.
Do not take Telmisartan Actavis - if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Telmisartan Actavis - Ako ste alergični na telmisartan ili neki drugi sastojak ovog lijeka (navedene u dijelu 6).
If you accidentally take too many tablets ask your doctor what to do or contact your nearest hospital emergency department immediately. 
Ako ste slučajno uzeli previše tableta, odmah se obratite svom liječniku ili u hitnu službu najbliže bolnice.
Telmisartan Actavis is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Telmisartan Actavis se ne preporučuje dojiljama te Vaš liječnik može odabrati drugo liječenje za Vas ako želite dojiti, osobito ako je Vaše dijete novorođenče ili je prerano rođeno.
This is confirmed by trough to peak ratios consistently above 80% seen after doses of 40 and 80 mg of telmisartan in placebo controlled clinical studies. 
Ovo je potvrđeno omjerima minimalnih do maksimalnih vrijednosti koje su konstantno bile iznad 80% nakon doza od 40 i 80 mg telmisartana u placebom kontroliranim kliničkim ispitivanjima.
Volume and/or sodium depletion should be corrected prior to administration of Telmisartan Actavis . 
Deplecija volumena i/ili natrija se mora korigirati prije primjene lijeka Telmisartan Actavis.
The risk is particularly high in combination with potassium sparing-diuretics and when combined with salt substitutes containing potassium. 
Rizik je osobito visok u kombinaciji s diureticima koji štede kalij i u kombinaciji s nadomjescima soli koje sadrže kalij.
As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia (see section 4.4). 
Poput ostalih lijekova koji djeluju na sustav renin-angiotenzin-aldosteron, telmisartan može izazvati hiperkalemiju (vidjeti dio 4.4).
The use of Telmisartan Actavis in children and adolescents up to the age of 18 years is not recommended. 
Primjena lijeka Telmisartan Actavis u djece i adolescenata do dobi od 18 godina se ne preporučuje.
At the beginning of the preventive therapy with Telmisartan Actavis 80 mg, blood pressure should be frequently monitored. 
Na početku preventivnog liječenja lijekom Telmisartan Actavis od 80 mg, krvni tlak treba redovito pratiti.
(See section 5.3). 
i 5.1).
- Diuretics ('water tablets'), especially if taken in high doses together with Telmisartan Actavis, 
- Diuretici („tablete za mokrenje“), osobito ako se uzimaju visoke doze zajedno s lijekom
Telmisartan Actavis may be less effective in lowering the blood pressure in black patients. 
Telmisartan Actavis može biti manje učinkovit u snižavanju krvnog tlaka u bolesnika crne rase.
What Telmisartan Actavis is and what it is used for 
Što je Telmisartan Actavis i za što se koristi
How to store Telmisartan Actavis Contents of the pack and other information 
Kako čuvati Telmisartan Actavis Sadržaj pakiranja i druge informacije
There is no experience regarding the administration of Telmisartan Actavis in patients with recent kidney transplantation. 
Ne postoji iskustvo u vezi primjene lijeka Telmisartan Actavis u bolesnika kojima je nedavno transplantiran bubreg.
Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC code: C09CA07. 
5.1 Farmakodinamička svojstva Farmakoterapijska skupina: Antagonisti angiotenzina II, čisti, ATK oznaka: C09CA07.
What you need to know before you take Telmisartan Actavis 
Što morate znati prije nego počnete uzimati Telmisartan Actavis
Some people feel dizzy or tired when taking Telmisartan Actavis. 
Neki ljudi osjećaju omaglicu ili umor kada uzimaju Telmisartan Actavis.
This applies especially to the medicines listed below taken at the same time with Telmisartan Actavis 
Ovo se osobito odnosi na lijekove koji su navedeni u nastavku, a uzimaju se istodobno s lijekom Telmisartan Actavis:
As observed for angiotensin converting enzyme inhibitors, telmisartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in nonblacks, possibly because of higher prevalence of low-renin states in the black hypertensive population. 
Kao što je uočeno za inhibitore angiotenzin konvertirajućeg enzima, telmisartan i drugi antagonisti angiotenzina su manje učinkoviti u snižavanju krvnog tlaka u osoba crne rase nego u osoba koje nisu crne rase, možda zbog veće prevalencije stanja sa sniženim vrijednostima renina u populaciji crne rase s hipertenzijom.
For reduction of cardiovascular events, the usual dose of Telmisartan Actavis is one 80 mg tablet once a day. 
Za smanjivanje kardiovaskularnih događaja, uobičajena doza lijeka Telmisartan Actavis je jedna tableta od 80 mg, jednom dnevno.
Other medicines and Telmisartan Actavis 
Drugi lijekovi i Telmisartan Actavis
The effect of Telmisartan Actavis may be reduced when you take NSAIDs (non steroidal anti-inflammatory drugs, e.g. aspirin or ibuprofen) or corticosteroids. 
Učinak lijeka Telmisartan Actavis se može smanjiti kada uzimate NSAIL (nesteroidne protupalne lijekove, npr. aspirin ili ibuprofen) ili kortikosteroide.
Angiotensin II is a substance produced in your body, which causes your blood vessels to narrow, thus increasing your blood pressure. 
Angiotenzin II je tvar koja se stvara u Vašem tijelu i dovodi do sužavanja krvnih žila, čime se povisuje krvni tlak.
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). 
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do
Telmisartan Actavis is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Telmisartan Actavis je kontraindiciran u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
Close-monitoring of serum potassium in at risk patients is recommended (see section 4.5). 
Preporučuje se pažljivo pratiti kalij u serumu rizičnih bolesnika (vidjeti dio 4.5).
Telmisartan Actavis is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile. 
Telmisartan Actavis se ne smije davati bolesnicima s kolestazom, bilijarnom opstrukcijom ili teškim oštećenjem jetre (vidjeti dio 4.3), s obzirom da se telmisartan uglavnom eliminira putem žuči.
You should consult with your doctor if you need to adjust the dose of your other medicine while taking Telmisartan Actavis. 
Potrebno je posavjetovati se s liječnikom ako trebate prilagodbu doze drugih lijekova dok uzimate Telmisartan
MINIMUM PARTICULARS TO APPEAR ON BLISTERS Blister 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER Blister
If any of the above applies to you, tell your doctor or pharmacist before taking Telmisartan Actavis. 
Ako se nešto od prethodno navedenog odnosi na Vas, obavijestite liječnika ili ljekarnika prije početka uzimanja lijeka Telmisartan Actavis.
In dogs renal tubular dilation and atrophy were observed. 
U pasa su uočene renalna tubularna dilatacija i atrofija.
Hepatic function abnormal / liver disorder 
Abnormalna funkcija jetre / poremećaj rada jetre
There are no adequate data from the use of Telmisartan Actavis in pregnant women. 
Ne postoje odgovarajući podaci o primjeni lijeka Telmisartan Actavis u trudnica.
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5% CI 0.931.10, p (non-inferiority) = 0.0019 at a margin of 1.13). 
Omjer hazarda za telmisartan u odnosu na ramipril bio je 1,01 (97,5% CI 0,93 - 1,10, p (neinferiornost) = 0,0019 na granici od 1,13).
Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased 
Sniženi hemoglobin, povišene vrijednosti mokraćne kiseline u krvi, povišeni jetreni enzimi, povišena kreatin-fosfokinaza u krvi
Telmisartan Actavis is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes. 
Telmisartan Actavis se također primjenjuje za smanjivanje kardiovaskularnih događaja (tj. srčanog udara ili moždanog udara) u rizičnih odraslih osoba koje imaju smanjenu ili prekinutu opskrbu krvlju srca ili nogu, ili su imale moždani udar, ili imaju šećernu bolest s visokim rizikom za oštećenje organa.
Angiotensin II receptor antagonists should not be initiated during pregnancy. 
Primjena antagonista receptora angiotenzina II ne smije se započinjati tijekom trudnoće.
Symptoms: The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia dizziness, increase in serum creatinine, and acute renal failure have also been reported. 
Simptomi: Najizraženije manifestacije predoziranja telmisartanom bile su hipotenzija i tahikardija; također su zabilježeni bradikardija, omaglica, porast kreatinina u serumu i akutno zatajenje bubrega.
In patients with liver problems the usual dose should not exceed 40 mg once daily. 
U bolesnika s oštećenom jetrom, uobičajena doza ne smije prelaziti 40 mg jednom dnevno.
After adjustment for age group effects mean SBP changes from baseline (primary objective) were -14.5 (1.7) mm Hg in the telmisartan 2 mg/kg group, -9.7 (1.7) mm Hg in the telmisartan 1 mg/kg group, and -6.0 (2.4) in the placebo group. 
Nakon prilagodbe dobnih učinaka skupine prosječna promjena SKT-a u odnosu na početnu vrijednost (primarni cilj) bila je -14.5 (1.7) mm Hg u skupini na 2 mg/kg telmisartana, - 9,7 (1,7) mm Hg u skupini na 1 mg/kg telmisartana, te - 6,0 (2,4) u skupini na placebu.
TRANSCEND randomized ACE-I intolerant patients with otherwise similar inclusion criteria as ONTARGET to telmisartan 80 mg (n = 2954) or placebo (n = 2972), both given on top of standard care. 
Bolesnici s netolerancijom na ACE-I randomizirani u TRANSCEND ispitivanju, s inače sličnim kriterijima uključivosti kao u ONTARGET ispitivanju, randomizirani su na telmisartan 80 mg (n=2954) ili placebo (n=2972), oboje davani povrh standardnog liječenja.
In the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/or in patients with intercurrent events, hyperkalaemia may be fatal. 
U starijih osoba, bolesnika s insuficijencijom bubrega, dijabetičara, bolesnika koji se istodobno liječe drugim lijekovima koji mogu povećati razinu kalija i/ili bolesnika s interkurentnim događajima, hiperkalemija može imati smrtni ishod.
- if you are taking any of the following medicines used to treat high blood pressure: an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. 
- ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka: ACE inhibitor (primjerice enalapril, lisinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću.
Urinary tract infection including cystitis, upper respiratory tract infection including pharyngitis and sinusitis Sepsis including fatal outcome1 
Infekcije mokraćnog sustava uključujući cistitis, infekcije gornjeg dišnog sustava uključujući faringitis i sinusitis Sepsa uključujući smrtni ishod 1
- Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy ('water tablets'), low-salt diet, diarrhoea, 
- Niski krvni tlak (hipotenzija), veća je vjerojatnost ove pojave ako ste dehidrirani (prekomjerni gubitak vode u tijelu) ili imate manjak soli zbog terapije diureticima (tablete za mokrenje),
You must tell your doctor if you think you are (or might become) pregnant. 
Morate obavijestiti svog liječnika ako mislite da ste (ili bi mogli postati) trudni.
Limited experience is available in patients with severe renal impairment or haemodialysis. 
Postoji ograničeno iskustvo u bolesnika s teškim oštećenjem bubrega ili bolesnika na hemodijalizi.
Telmisartan Actavis blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. 
Telmisartan Actavis blokira učinak angiotenzina II, tako da se krvne žile šire, a krvni tlak snižava.
In the PRoFESS trial, an increased incidence of sepsis was observed with telmisartan compared with placebo. 
U ispitivanju PRoFESS, uočena je veća incidencija sepse s telmisartanom u usporedbi s placebom.
When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy such as Telmisartan Actavis. 
Prilikom upravljanja vozilima ili strojevima, povremeno može doći do pojave omaglice ili omamljenosti, kada se uzima antihipertenzivna terapija poput lijeka Telmisartan Actavis.
When Telmisartan Actavis is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended. 
Kada se Telmisartan Actavis primjenjuje u bolesnika s poremećenom funkcijom bubrega, preporučuje se povremeno pratiti vrijednosti kalija i kreatinina u serumu.
Telmisartan Actavis contains the active substance telmisartan which belongs to a class of medicines known as angiotensin II receptor antagonists. 
Telmisartan Actavis sadrži djelatnu tvar telmisartan i pripada grupi lijekova poznatih kao antagonisti receptora angiotenzina II.
The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia. 
Hiperkalemija Primjena lijekova koji utječu na sustav renin-angiotenzin-aldosteron može izazvati hiperkalemiju.
After oral (and intravenous) administration telmisartan is nearly exclusively excreted with the faeces, mainly as unchanged compound. 
Nakon peroralne (i intravenske) primjene, telmisartan se gotovo isključivo izlučuje fecesom,
In patients with kidney problems a lower starting dose of 20 mg is recommended. 
U bolesnika s oštećenim bubrezima preporučuje se početna doza od 20 mg.
Symptomatic hypotension, especially after the first dose of Telmisartan Actavis, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. 
Simptomatska hipotenzija, osobito nakon prve doze lijeka Telmisartan Actavis, može se pojaviti u bolesnika koji imaju depleciju volumena i/ili natrija zbog snažne terapije diureticima, prehrane s ograničenim unosom soli, proljeva ili povraćanja.
Visual disturbance 
Poremećaji oka
The pharmacokinetics of two doses of telmisartan were assessed as a secondary objective in hypertensive patients (n = 57) aged 6 to < 18 years after taking telmisartan 1 mg/kg or 2 mg/kg over a four-week treatment period. 
Farmakokinetika dviju doza telmisartana ocjenjivana je kao sekundarni cilj kod hipertenzivnih bolesnika (n = 57) u dobi od 6 do < 18 godina starosti nakon uzimanja telmisartana 1 mg/kg ili
Telmisartan Actavis should be used only with caution in patients with mild to moderate hepatic impairment. 
Telmisartan Actavis se treba primjenjivati isključivo s oprezom u bolesnika s blagim do umjerenim oštećenjem jetre.
Keep the container tightly closed in order to protect from light. 
Spremnik čuvati čvrsto zatvorenim radi zaštite od svjetlosti.
The safety and efficacy of telmisartan in children and adolescents aged below 18 years have not been established. 
Sigurnost i djelotvornost telmisartana nije utvrđena u djece i adolescenata mlađih od 18 godina
Because no information is available regarding the use of Telmisartan Actavis during breast-feeding, Telmisartan Actavis is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant. 
Budući da ne postoje dostupni podaci o primjeni lijeka Telmisartan Actavis tijekom dojenja, primjena lijeka Telmisartan Actavis se ne preporučuje i prednost se daje drugim lijekovima s bolje utvrđenim sigurnosnim profilima tijekom dojenja, osobito tijekom razdoblja dojenja novorođenčeta ili nedonoščeta.
The most common symptoms of telmisartan overdose are low blood pressure (hypotension) and fast heart beat (tachycardia). 
Najčešći simptomi predoziranja telmisartanom su sniženi krvni tlak (hipotenzija) i ubrzan rad srca
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, 
Sepsa* (često nazvana „trovanje krvi“ je teška infekcija s upalnim odgovorom cijelog organizma što može dovesti do smrtnog ishoda), povećanje određenih bijelih krvnih stanica (eozinofilija), nizak broj krvnih pločica (trombocitopenija), teška alergijska reakcija (anafilaktička reakcija), alergijska reakcija
Most cases of hepatic function abnormal / liver disorder from post-marketing experience occurred in Japanese patients. 
Većina slučajeva abnormalne funkcije jetre / poremećaja rada jetre nakon stavljanja lijeka u promet, pojavila se u bolesnika u Japanu.
Non-steroidal anti-inflammatory medicinal products NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and nonselective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists. 
NSAIL (tj. acetilsalicilna kiselina u protuupalnim režimima doziranja, COX-2-inhibitori i neselektivni NSAIL) mogu smanjiti antihipertenzivni učinak antagonista receptora angiotenzina II.
Telmisartan Actavis may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). 
Telmisartan Actavis može povećati učinak snižavanja krvnog tlaka drugih lijekova koji se primjenjuju u liječenju visokog krvnog tlaka ili lijekova s potencijalnim učincima na snižavanje krvnog tlaka (npr.
The concomitant use of Telmisartan Actavis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 
Istodobna primjena lijeka Telmisartan Actavis s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
Al/Al blister packs: 14, 28, 30, 56, 84, 90, 98 and 100 tablets. 
Al/Al blisteri:14, 28, 30, 56, 84, 90, 98 i 100 tableta.
Talk to your doctor if you are suffering or have ever suffered from any of the following conditions or illnesses: - Kidney disease or kidney transplant. 
Obavijestite svog liječnika ako imate ili ste ikada imali neko od sljedećih stanja ili bolesti:
For treatment of high blood pressure, the usual dose of Telmisartan Actavis for most patients is one 40 mg tablet once a day to control blood pressure over the 24 hour period. 
Uobičajena doza lijeka Telmisartan Actavis za većinu bolesnika je jedna tableta od 40 mg jednom dnevno za kontrolu krvnog tlaka tijekom 24 sata.
Other conditions with stimulation of the renin-angiotensin-aldosterone system In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system such as telmisartan has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8). 
U bolesnika čiji vaskularni tonus i funkcija bubrega ovise prvenstveno o djelovanju sustava renin angiotenzin-aldosteron (npr. bolesnici s teškim kongestivnim zatajenjem srca ili osnovnom bolešću bubrega, uključujući stenozu bubrežne arterije), liječenje lijekovima koji utječu na ovaj sustav, kao što je telmisartan, je povezano s akutnom hipotenzijom, hiperazotemijom, oligurijom ili rijetko, akutnim zatajenjem bubrega (vidjeti dio 4.8).
SPECIAL STORAGE CONDITIONS Keep the container tightly closed in order to protect from light. 
POSEBNE MJERE ČUVANJA Spremnik čuvati čvrsto zatvorenim radi zaštite od svjetlosti.
If concomitant use is indicated because of documented hypokalaemia, they should be used with caution and with frequent monitoring of serum potassium. 
Ako je indicirana istodobna primjena zbog zabilježene hipokalemije, primjenjuje ih se oprezno i uz učestalo praćenje kalija u serumu.
Telmisartan Actavis is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Telmisartan Actavis se ne preporučuje u ranoj trudnoći, a ne smije se uzeti ako ste više od 3 mjeseca trudni jer može uzrokovati ozbiljnu štetu za vaše dijete ako se uzima u toj fazi (vidjeti dio o trudnoći).
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7% in the telmisartan and 17.0% in the placebo groups with a hazard ratio of 0.92 (95% CI 0.81-1.05, p = 0.22)]. 
Nije pronađena statistički značajna razlika u incidenciji primarnog složenog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7% u skupini na telmisartanu i 17,0% u skupini na placebu s omjerom hazarda od 0,92 (95% CI 0,81 - 1,05, p = 0,22)].
Telmisartan Actavis is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. 
Telmisartan Actavis se ne preporučuje u ranoj trudnoći te se ne smije uzimati ako ste trudni dulje od 3 mjeseca, jer može izazvati teška oštećenja kod Vašeg djeteta ako se primjenjuje nakon trećeg mjeseca trudnoće.
If you stop taking Telmisartan Actavis 
Ako prestanete uzimati Telmisartan Actavis
Such conditions should be corrected before the administration of Telmisartan Actavis . 
Takva stanja moraju se korigirati prije primjene lijeka Telmisartan Actavis.
In addition, there was a significantly higher incidence of hyperkalaemia, renal failure, hypotension and syncope in the combination arm. 
Nadalje, u skupini koja je primala kombinaciju postojala je znatno veća incidencija pojave hiperkalemije, zatajenja bubrega, hipotenzije i sinkope.
In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. 
U pojedinih bolesnika s narušenom funkcijom bubrega (npr. dehidrirani bolesnici ili stariji bolesnici s narušenom funkcijom bubrega), istodobna primjena antagonista receptora angiotenzina II i inhibitora ciklooksigenaze može rezultirati daljnjim pogoršanjem bubrežne funkcije, uključujući moguće akutno zatajenje bubrega koje je obično reverzibilno.